Avadel Pharmaceuticals Completes Enrollment in the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
17. Dezember 2019 08:00 ET
|
Avadel Pharmaceuticals plc
- - -A total of 212 patients enrolled in the REST-ON study exceeds the trial’s enrollment target of 205- - -Topline data from the REST-ON study expected in Q2 2020 DUBLIN, Ireland, Dec. 17, 2019 ...
Avadel Pharmaceuticals Receives U.S. FDA Approval for Nouress™ (AV001), a Cysteine Hydrochloride Injection for Treating Neonate Patients Requiring Total Parental Nutrition (TPN)
16. Dezember 2019 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
Avadel Pharmaceuticals Appoints Dr. Mark McCamish to its Board of Directors
10. Dezember 2019 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
Avadel Pharmaceuticals Announces Key Appointments to Leadership Team To Support Continued Transformation and the Advancement of FT218
02. Dezember 2019 08:00 ET
|
Avadel Pharmaceuticals plc
- - -Thomas S. McHugh appointed as Chief Financial Officer- - -Dr. Jason Vaughn appointed Senior Vice President of Technical Operations DUBLIN, Ireland, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Avadel...
Avadel Pharmaceuticals Achieves Enrollment Target in REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
25. November 2019 08:00 ET
|
Avadel Pharmaceuticals plc
205 patients enrolled; additional patients currently in screening will be allowed to enroll if eligible Topline data from the REST-ON study expected in Q2 2020 DUBLIN, Ireland, Nov. 25, 2019 ...
Avadel Pharmaceuticals to Present at Two Upcoming Investor Conferences
21. November 2019 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
Avadel Pharmaceuticals Reports Third Quarter 2019 Financial Results and Raises Revenue Guidance for FY2019
12. November 2019 07:00 ET
|
Avadel Pharmaceuticals plc
Enrollment currently at 200 patients for the pivotal REST-ON Phase 3 study (97.5% complete); the Company currently expects to complete patient enrollment by end of 2019, with data readout expected in...
Avadel Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 12th
29. Oktober 2019 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
Avadel Announces Resignation of Kevin Kotler from Board of Directors
04. Oktober 2019 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, a once-nightly formulation of sodium oxybate, for narcolepsy,...
Avadel Pharmaceuticals Announces Pharmacokinetic (PK) Data for Once-Nightly FT218 that will be Included in an Oral Presentation at the World Sleep 2019 Congress on September 25th
24. September 2019 07:30 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate,...